You will not be allowed to compare more than 4 products at a time
View compare
Building the Future of Low-Cost, Reproducible Life-Science Reagents
Atheris Bio develops chemically defined, animal-free media and reagent platforms for research, diagnostics, vaccines, and therapeutic development—delivering consistent performance at dramatically lower cost.
THE PROBLEM
Life-Science Research and Therapeutic Development Still Rely on Variable, High-Cost Inputs
Across research laboratories, vaccine development programs, and therapeutic pipelines, biological reagents remain expensive, inconsistent, and poorly defined.
Key Industry Challenges
- Serum and protein-based reagents introduce variability
- High costs limit experimental scale and access
- Poor reproducibility slows translation to therapeutics
- Animal-derived components complicate regulatory pathways
Investor Insight
Scientific progress is constrained by the cost and inconsistency of foundational reagents.
THE ATHERIS BIO SOLUTION
Defined Reagents Engineered for Cost, Consistency, and Translation
Atheris Bio replaces serum- and protein-dependent systems with chemically defined, animal-free formulations designed to support:
- Reliable research outcomes
- Efficient therapeutic and vaccine development
- Seamless transition from research to manufacturing
Our platforms reduce variability at the source—where experiments, processes, and therapies begin.
FOCUS PLATFORMS
Focused Technologies. Broad Application.
Serum-Free Mycobacterial Media
For reproducible TB, BCG, and NTM research, diagnostics, and vaccine development.
Protein-Free HEK293T Media
For consistent viral vector research and therapeutic development.
Defined Reagent Platforms
Modular, scalable systems designed to support research, process development, and manufacturing readiness.
MARKETS WE SERVE
Supporting the Full Life-Science Pipeline
- 🎓 Academic & Translational Research
- 🧬 Therapeutic & Gene Therapy Developers
- 💉 Vaccine Research & Manufacturing Programs
- 🦠 Diagnostic Developers & Clinical Labs
- 🏢 Biotech Startups, CROs, and CDMOs
Market Reality
These markets increasingly demand defined, reproducible, and cost-efficient inputs.
COMPETITIVE ADVANTAGE
Why Atheris Bio Is Different
- Lower cost than serum-based alternatives
- Fully defined, animal-free formulations
- Built for reproducibility across labs and scales
- Supports regulatory-aligned development
- Platform-driven product expansion
Investor Takeaway
Reducing reagent variability improves outcomes across research, vaccines, and therapeutics.
TRACTION & ROADMAP
From Research Validation to Broad Adoption
Current Progress
- Platform R&D and validation underway
- Early customer discovery across research and biotech
- Defined initial product lines
Next Milestones
- Research-use product launches
- Strategic partnerships
- Expansion into therapeutic and vaccine workflows
TEAM & EXECUTION
Built by Scientists Who Understand Translation
Atheris Bio is driven by a multidisciplinary team with expertise in:
- Biological reagent design
- Cell and molecular biology
- Diagnostic and therapeutic development
- Scalable life-science platforms
Execution Focus
Scientific rigor, reproducibility, and real-world usability.
INVESTMENT OPPORTUNITY
Invest in the Foundation of Reproducible Life Science
As research, vaccines, and therapeutics demand greater consistency and lower cost, defined reagent platforms become essential infrastructure.
Atheris Bio is positioned to supply that foundation.